Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arkansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arkansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arkansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Jamie Burton (NPI 1073737227)

Field	Value
Entity Type	Individual
Organization	Jamie Burton
Address	8901 Carti Way
City	Little Rock
State	AR
ZIP	72205
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	April 12, 2007

Payer Source	Total Paid
Medicare	$2.8M
Medicaid	$0

Key Findings

This clinician’s Medicare business is concentrated in high-cost oncology infusions: total Medicare revenue is $2.8M and the top three Medicare codes (J9271, J9299, J0897) together account for 73.0% of that revenue. The code mix—dominant use of J9271 (pembrolizumab), J9299 (nivolumab), and J0897 (denosumab)—indicates the practice is primarily delivering immune checkpoint inhibitors and bone-modifying therapy rather than being centered on office-only E/M visits or diagnostic testing. This profile is consistent with a medical oncology infusion practice focused on systemic anti-cancer therapies.

Revenue concentration is highly skewed toward a single agent: J9271 alone represents $1.3M and 46.3% of this provider’s Medicare revenue, showing that nearly half of Medicare income comes from pembrolizumab administration. The precomputed top-3 share of 73.0% underscores reliance on a very small set of drug administration codes for the bulk of Medicare revenue, which has implications for drug purchasing, inventory management, and payer contracting negotiations.

Payer mix is effectively single-payer with respect to public programs: Medicare activity is substantial at $2.8M while there is no Medicaid billing on file. This means the provider’s public-payer exposure and risk are concentrated in Medicare, and Medicaid does not contribute to observed revenue or service-volume patterns in the dataset.

Competitive standing for key immunotherapy codes is strong on a national scale: J9271 ranks #130 of 1841 providers nationally and is described as "notably above typical national volume for this code," signaling above-average infusion volumes of pembrolizumab relative to peers. J9299 ranks #161 of 505 providers (68th percentile) and is described as typical, while J0897 ranks #639 of 10057 providers (94th percentile) and is likewise unremarkable in volume; overall the provider appears to be a meaningful national-volume performer for at least one high-revenue immunotherapy.

Several non-drug CPTs also show unusually high relative volume and support a high-throughput infusion operation: 96413 (chemotherapy administration) ranks in the 98th percentile and is labeled "notably above typical national volume," 96375 and 96417 are likewise described as notably above-typical volumes, and 99215 and 99213 E/M codes are extreme to notable outliers in national rank. Together these patterns indicate frequent complex outpatient visits and repeated infusion encounters that align with an oncology infusion workflow.

The absence of Medicaid billing is a distinguishing business signal: "none below — this provider has no Medicaid billing on file," which suggests either a payer mix skewed toward Medicare and commercial payers, credentialing or paneling choices that exclude Medicaid, or simply no billed services to Medicaid beneficiaries during the reporting window. Analysts should treat this provider as effectively single-payer (Medicare) in public-data analyses and be cautious generalizing to Medicaid populations.

Tenure is long enough to support established referral flows: the NPI was enumerated on 2007-04-12 (~19 years ago), indicating the provider has had nearly two decades of potential Medicare participation and practice presence. That longevity, combined with high-volume immunotherapy billing, suggests an established oncology practice rather than a new or incidental infrequent infuser.

Procedure-level outliers and their operational implications are notable: high national-percentile ranks described as "notably above typical" or "extreme outlier" for codes such as J9271, 96413, 96375, 96417, 99215, and 99213 imply sustained high utilization of infusion and complex E/M services. For payers and competitors, this signals a high-capacity infusion center with downstream cost and utilization implications for oncology drug spend and infusion suite resource planning.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

88 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	29,400	$40	$1.3M
J9299	Injection, nivolumab, 1 mg	20,180	$20	$484.3K
J0897	Injection, denosumab, 1 mg	13,680	$20	$246.2K
Q5126	Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg	3,940	$60	$220.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	810	$90	$69.5K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	490	$120	$60.6K
J1437	Injection, ferric derisomaltose, 10 mg	3,500	$20	$59.5K
J0885	Injection, epoetin alfa, (for non-esrd use), 1000 units	9,490	$10	$57K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	480	$90	$42.2K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	1,040	$40	$37.4K

Showing 1–10 of 88

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 88 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arkansas Distribution

Jamie Burton — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arkansas

Full comparison — all codes billed, vs. state median

88 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	6	40	20,700	$40	$896.3K
J9299	11	30	15,660	$20	$432.9K
Q5126	2	10	3,210	$60	$174.1K
J1569	12	10	2,560	$40	$120.3K
J1437	19	20	6,450	$20	$107.8K
J0897	14	160	2,580	$20	$89.7K
J0885	11	40	4,070	$10	$38K
96413	12	80	380	$90	$36.6K
99214	744	4,300	130	$70	$18.8K
88185	7	20	780	$20	$18.5K

Showing 1–10 of 88

Related Providers

Other providers that share a Tax Identification Number (TIN) with Jamie Burton, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Central Arkansas Radiation Therapy Institute Inc	AR	Hematology & Oncology Physician	$0	$11M
Central Arkansas Radiation Therapy Institute Inc	AR	Radiation Oncology Physician	$6.7M	$3.6M
Kamal Patel	AR	Hematology & Oncology Physician	$5.7M	$0
Ryan Hall	AR	Hematology & Oncology Physician	$4.6M	$0
Balagopalan Nair	AR	Hematology & Oncology Physician	$4.1M	$0
Lawrence Mendelsohn	AR	Hematology & Oncology Physician	$3.4M	$0
Kewen Jauss	AR	Hematology & Oncology Physician	$2.8M	$0
Mariann Harrington	AR	Hematology & Oncology Physician	$2.7M	$0
Appalanaidu Sasapu	AR	Hematology & Oncology Physician	$2.6M	$0
Derek Middleton	AR	Hematology & Oncology Physician	$2.5M	$0

Nearby Providers

Other providers in the same ZIP code as Jamie Burton, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
University Of Arkansas For Medical Sciences	AR	General Acute Care Hospital	$0	$87.2M
University Of Arkansas For Medical Sciences	AR	Internal Medicine Physician	$0	$28.6M
University Of Arkansas For Medical Sciences	AR	Pediatrics Physician	$0	$27.6M
Arkansas Department Of Health Immunizations	AR	Public Health or Welfare Agency	$0	$19.3M
Baptist Health	AR	General Acute Care Hospital	$0	$16.4M
Arkansas Department Of Health Family Planning Clinic	AR	Public Health or Welfare Agency	$0	$15.6M
Pediatrix Medical Group Of Arkansas PA	AR	Neonatal-Perinatal Medicine Physician	$0	$14.6M
Chenal Family Therapy, Plc	AR	Mental Health Counselor	$0	$12.2M
Francis A. Allen School For Exceptional Children, Inc.	AR	Developmentally Disabled Services Day Training Agency	$0	$11.9M
Arkansas Department Of Health Std	AR	Public Health or Welfare Agency	$0	$8.4M

Jamie Burton — Billing Profile & Reimbursement Data

Sign up for Jamie Burton — Billing Profile & Reimbursement Data policy alerts

Jamie Burton — Billing Profile & Reimbursement Data

Sign up for Jamie Burton — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References